1h Free Analyst Time
The publisher has been monitoring the female infertility drugs market and it is poised to grow by $538.69 mn during 2021-2025, progressing at a CAGR of 4.71% during the forecast period. The report on the female infertility drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the adverse outcomes and high cost of non-therapeutics and high prevalence of female infertility.
The female infertility drugs market analysis includes the route of administration segment and geographic landscape.
The female infertility drugs market is segmented as below:
By Route of Administration
- Parenteral
- Oral
- Vaginal
By Geographical Landscape
- North America
- Europe
- Asia
- ROW
This study identifies the high-risk factors for female infertility as one of the prime reasons driving the female infertility drugs market growth during the next few years.
The report on female infertility drugs market covers the following areas:
- Female infertility drugs market sizing
- Female infertility drugs market forecast
- Female infertility drugs market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading female infertility drugs market vendors that include AbbVie Inc., Aurobindo Pharma Ltd., Dr. Reddys Laboratories Ltd., Ferring B.V., Lupin Ltd., Merck KGaA, Mylan NV, Novartis AG, Sanofi SA, and Takeda Pharmaceutical Co. Ltd. Also, the female infertility drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary- Market Overview
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2020
- Market outlook: Forecast for 2020 - 2025
Five Forces Analysis
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Route of administration
- Market segments
- Comparison by Route of administration
- Parenteral - Market size and forecast 2020-2025
- Oral - Market size and forecast 2020-2025
- Vaginal - Market size and forecast 2020-2025
- Market opportunity by Route of administration
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2020-2025
- Europe - Market size and forecast 2020-2025
- Asia - Market size and forecast 2020-2025
- ROW - Market size and forecast 2020-2025
- Key leading countries
- Market opportunity By Geographical Landscape
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- AbbVie Inc.
- Aurobindo Pharma Ltd.
- Dr. Reddys Laboratories Ltd.
- Ferring B.V.
- Lupin Ltd.
- Merck KGaA
- Mylan NV
- Novartis AG
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
Exhibits
- Key Finding 1
- Key Finding 2
- Key Finding 3
- Key Finding 5
- Key Finding 6
- Key Finding 7
- Key Finding 8
- Parent market
- Market characteristics
- Offerings of vendors included in the market definition
- Market segments
- Global - Market size and forecast 2020 - 2025 ($ million)
- Global market: Year-over-year growth 2020 - 2025 (%)
- Five forces analysis 2020 & 2025
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition - Five forces 2020
- Route of administration - Market share 2020-2025 (%)
- Comparison by Route of administration
- Parenteral - Market size and forecast 2020-2025 ($ million)
- Parenteral - Year-over-year growth 2020-2025 (%)
- Oral - Market size and forecast 2020-2025 ($ million)
- Oral - Year-over-year growth 2020-2025 (%)
- Vaginal - Market size and forecast 2020-2025 ($ million)
- Vaginal - Year-over-year growth 2020-2025 (%)
- Market opportunity by Route of administration
- Customer landscape
- Market share By Geographical Landscape 2020-2025 (%)
- Geographic comparison
- North America - Market size and forecast 2020-2025 ($ million)
- North America - Year-over-year growth 2020-2025 (%)
- Europe - Market size and forecast 2020-2025 ($ million)
- Europe - Year-over-year growth 2020-2025 (%)
- Asia - Market size and forecast 2020-2025 ($ million)
- Asia - Year-over-year growth 2020-2025 (%)
- ROW - Market size and forecast 2020-2025 ($ million)
- ROW - Year-over-year growth 2020-2025 (%)
- Key leading countries
- Market opportunity By Geographical Landscape ($ million)
- Impact of drivers and challenges
- Vendor landscape
- Landscape disruption
- Industry risks
- Vendors covered
- Market positioning of vendors
- AbbVie Inc. - Overview
- AbbVie Inc. - Product and service
- AbbVie Inc. - Key offerings
- AbbVie Inc. - Key customers
- AbbVie Inc. - Segment focus
- Aurobindo Pharma Ltd. - Overview
- Aurobindo Pharma Ltd. - Product and service
- Aurobindo Pharma Ltd. - Key offerings
- Aurobindo Pharma Ltd. - Key customers
- Aurobindo Pharma Ltd. - Segment focus
- Dr. Reddys Laboratories Ltd. - Overview
- Dr. Reddys Laboratories Ltd. - Business segments
- Dr. Reddys Laboratories Ltd. - Key offerings
- Dr. Reddys Laboratories Ltd. - Key customers
- Dr. Reddys Laboratories Ltd. - Segment focus
- Ferring B.V. - Overview
- Ferring B.V. - Product and service
- Ferring B.V. - Key offerings
- Ferring B.V. - Key customers
- Ferring B.V. - Segment focus
- Lupin Ltd. - Overview
- Lupin Ltd. - Product and service
- Lupin Ltd. - Key offerings
- Lupin Ltd. - Key customers
- Lupin Ltd. - Segment focus
- Merck KGaA - Overview
- Merck KGaA - Business segments
- Merck KGaA - Key offerings
- Merck KGaA - Key customers
- Merck KGaA - Segment focus
- Mylan NV - Overview
- Mylan NV - Business segments
- Mylan NV - Key offerings
- Mylan NV - Key customers
- Mylan NV - Segment focus
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key offerings
- Novartis AG - Key customers
- Novartis AG - Segment focus
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key offerings
- Sanofi SA - Key customers
- Sanofi SA - Segment focus
- Takeda Pharmaceutical Co. Ltd. - Overview
- Takeda Pharmaceutical Co. Ltd. - Product and service
- Takeda Pharmaceutical Co. Ltd. - Key offerings
- Takeda Pharmaceutical Co. Ltd. - Key customers
- Takeda Pharmaceutical Co. Ltd. - Segment focus
- Currency conversion rates for US$
- Research Methodology
- Validation techniques employed for market sizing
- Information sources
- List of abbreviations
Executive Summary
The publisher recognizes the following companies as the key players in the global female infertility drugs market: AbbVie Inc., Aurobindo Pharma Ltd., Dr. Reddys Laboratories Ltd., Ferring B.V., Lupin Ltd., Merck KGaA, Mylan NV, Novartis AG, Sanofi SA, and Takeda Pharmaceutical Co. Ltd.Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is high-risk factors for female infertility.`
According to the report, one of the major drivers for this market is the adverse outcomes and high cost of non-therapeutics.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Aurobindo Pharma Ltd.
- Dr. Reddys Laboratories Ltd.
- Ferring B.V.
- Lupin Ltd.
- Merck KGaA
- Mylan NV
- Novartis AG
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd.
